Hajar Belghacham

Clinical Efficacy and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis : A 10-Year Single-Centre Retrospective Observational Study

Hajar Belghacham, S. Slimani, K. Hjiej, M. Bourrouk, S. Ouzegza, I. Beogo, M. A. Mnaili, Y. Benmoh & A. Bourazza · Asian Journal of Research and Reports in Neurology · 2026

Background: Fingolimod is an oral disease-modifying therapy approved for the treatment of highly active relapsing forms of multiple sclerosis (MS). Real-world data remain essential for assessing its long-term effectiveness and safety in routine clinical practice. Objective: The s...

Open access Research Article 10.9734/ajorrin/2026/v9i1190

Parkinsonism as an Initial Presentation of Sporadic Creutzfeldt-Jakob Disease: A Case Report and Review of the Literature

Hajar Belghacham, Sarah Slimani, Soumia Ouzagza, Mohamed Amine Mnaili, Youssouf Benmoh & Ahmed bourazza · Asian Journal of Research and Reports in Neurology · 2026

Creutzfeldt-Jakob disease is a rare, rapidly progressive prion disorder that most commonly presents with cognitive decline, myoclonus, cerebellar signs, and other neuropsychiatric manifestations. Atypical presentations may delay recognition, particularly when the initial clinical...

Open access Research Article 10.9734/ajorrin/2026/v9i1182

Treatment of Multiple Sclerosis with Anti-CD20 Therapies: Experience of the Mohammed V Military Teaching Hospital

Sarah Slimani, Manal Bourrouk, Kaoutar Hjiej, Hajar Belghacham, Ihsane Hmamouchi, Mohamed Amine Mnaili, Youssouf Ben Moh & Ahmed bourazza · Asian Journal of Research and Reports in Neurology · 2026

Background: Anti-CD20 monoclonal antibodies, including rituximab (RTX) and ocrelizumab (OCR), have markedly improved the management of multiple sclerosis (MS) by reducing inflammatory disease activity. However, local evidence regarding their effectiveness and safety in real-world...

Open access Research Article 10.9734/ajorrin/2026/v9i1187